Bioiberica to participate at the CPhl Worldwide fair to be held this week in Frankfurt

Bioiberica has again confirmed their presence at the CPhI Worldwide fair, the most important international event for producers of ingredients and pharmacologic solutions. This year, the CPhl will be held in Frankfurt (Germany) on 24-26 October 2017, and will be attended by more than 2,500 exhibitors from 153 countries and more than 42,000 professionals from the pharmaceutical sector.

At Booth 90D81 in the Exhibitors area, our Heparin Science and Human Health divisions will present the many pharmaceutical active ingredients our company specializes in (heparin, chondroitin sulfate, glucosamine and hyaluronic acid), along with our range of branded ingredients and finished products for human healthcare.

This event is a unique occasion for Bioiberica to identify business opportunities and to establish new alliances. It is also an education platform that allows us to learn about the latest novelties available.

In this year’s fair, we will highlight b-2Cool®, Bioiberica’s Type II native collagen. Some joint diseases that provoke inflammation and cartilage erosion are caused by an immune response against the joints’ endogenous collagen. An orally taken, low dose of b-2Cool® can modulate that immune response.

Among our finished products, we will also highlight the international launch of Hialsorb Intraarticular. Hialsorb Intraarticular is a single use injection with highly concentrated hyaluronic acid for the intra-articular treatment of osteoarthritis and other degenerative joint disorders. Hialsorb Intraarticular has been given the designation “Medical Device” by the European Union.

Bioiberica is a company with more than 40 years of experience under their belt in the identification and production of biomolecules for the pharmaceutical industry. Heparin is the product Bioiberica has specialized in since their beginnings in 1975, become a world leader in the production of this anticoagulant and antithrombotic drug. More precisely, one out of every five heparin doses administered worldwide has been developed and produced by Bioiberica.